找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Biopharmaceutical Applied Statistics Symposium; Volume 3 Pharmaceuti Karl E. Peace,Ding-Geng Chen,Sandeep Menon Book 2018 Springer Nature S

[复制链接]
楼主: Ingrown-Toenail
发表于 2025-4-1 02:38:54 | 显示全部楼层
Interesting Applications from Three Decades of Biostatistical Consulting,d later dose discrimination, as well as illustrating the need to carefully define the trial objective. The last example provides an overview of assessing whether evidence exists from two Phase II trials of angina to support conducting a Phase III trial at either a b.i.d. or t.i.d. drug.
发表于 2025-4-1 09:01:02 | 显示全部楼层
Overview of Omics Biomarker Discovery and Design Considerations for Biomarker-Informed Clinical Trih-throughput omics technologies has enabled scientists to discover new biomarkers with low cost. Leveraging available technology and biomarker information, novel biomarker-based clinical trial designs have been proposed and have proven beneficial to many clinical programs. In this chapter, we discus
发表于 2025-4-1 10:43:54 | 显示全部楼层
Phase 3 Oncology Trials of Personalized Medicines with Adaptive Subpopulation Selection,ever, there is great uncertainty about drug activity in a subpopulation when designing a confirmatory trial in practice and it is logical to take a two-stage adaptive approach. The first stage de-selects (or prunes) non-performing subpopulations at an interim analysis, and the second stage pools the
发表于 2025-4-1 17:19:47 | 显示全部楼层
,Synergy or Additivity—The Importance of Defining the Primary Endpoint and the Approach to Its Statio therapeutic agents depends to a critical degree on how “synergy” is defined and how the data are analyzed. To illustrate these points, a hypothetical example based on an actual case is discussed. In the example, a common set of clinical trials was analyzed by two different organizations with two d
发表于 2025-4-1 19:27:13 | 显示全部楼层
Recycling of Significance Levels in Testing Multiple Hypotheses of Confirmatory Clinical Trials, types and sometimes into other lower types. The primary hypotheses enjoy a special status; if the trial wins for one or more primary hypotheses, then one can characterize clinically relevant benefits of the study treatment. This framework of classifying hypotheses based on their importance into pri
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-22 17:04
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表